Evidence map›Paper›PMID 31760376›Full record

ArticleMolecular therapy. Nucleic acids2019

Characterization of a Prostate- and Prostate Cancer-Specific Circular RNA Encoded by the Androgen Receptor Gene.

Jindan Luo, Yinan Li, Wei Zheng, Ning Xie, Yao Shi, Zhi Long, Liping Xie, Ladan Fazli, Dahong Zhang, Martin Gleave and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Nucleic acids, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Role of Circular RNAs in Prostate Cancer.Current medicinal chemistry · 2024
    Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Androgen Receptor-Related Non-coding RNAs in Prostate Cancer.Frontiers in cell and developmental biology · 2021
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jindan LuoDepartment of Urology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.
Yinan LiDepartment of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada; Department of Vascular Surgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China. Electronic address: liyinan0402@126.com.
Wei ZhengDepartment of Urology, Zhejiang Provincial People's Hospital, Hangzhou 310024, China.
Ning XieDepartment of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
Yao ShiDepartment of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
Zhi LongDepartment of Urology, Third Xiangya Hospital, Central South University, Changsha 410013, China.
Liping XieDepartment of Urology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.
Ladan FazliDepartment of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
Dahong ZhangDepartment of Urology, Third Xiangya Hospital, Central South University, Changsha 410013, China.
Martin GleaveDepartment of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
Xuesen DongDepartment of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada. Electronic address: xdong@prostatecenter.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The linear mRNAs transcribed under alternative RNA splicing and overexpression/amplification of the androgen receptor (AR) gene are poor prognostic biomarkers of castrate-resistant prostate cancer (PCa). Whether the AR gene also transcribes non-coding circular RNAs that are associated with PCa development and tumor progression remains unclear. Here, we identified and characterized an AR circular RNA, called circAR3, that is widely expressed in PCa cell models and prostate tumors. circAR3 can be secreted into culture media of PCa cell lines and is detectable in the serum from mice bearing PCa xenografts. In PCa patient tissues, circAR3 is highly expressed in benign prostate and hormone naive PCa but downregulated when tumors were treated with neoadjuvant hormone therapy and further reduced when tumors progressed to the castrate-resistant stage. However, circAR3 levels in plasma are extremely low in patients with benign prostate, are upregulated in PCa patients with high Gleason scores and lymph node metastasis, and become undetectable in men after radical prostatectomy. circAR3 does not affect AR signaling, PCa cell proliferation, and invasion rates. Our results demonstrated that the origin of the detectable plasma circAR3 is from the prostate/PCa. Plasma circAR3 may be developed to be a PCa biomarker to monitor PCa development and tumor progression.

Indexed as

alternative RNA splicingandrogen receptorAR splice variantcell-free circular RNAcircAR3circular RNAprostate cancer

Identifiers

PMID31760376
PMCPMC6883311

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.